



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 


PRODUCT INFORMATION



R-268712

Item No. 36810

CAS Registry No.: 879487-87-3
Formal Name: 4-[2-fluoro-5-[3-(6-methyl-2-pyridinyl)-1H-pyrazol-4-yl]phenyl]-1H-pyrazole-1-ethanol
MF: C₂₀H₁₈FN₅O
FW: 363.4
Purity: ≥98%
UV/Vis.: λ_{max}: 230, 252, 290 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

R-268712 is supplied as a crystalline solid. A stock solution may be made by dissolving the R-268712 in the solvent of choice, which should be purged with an inert gas. R-268712 is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of R-268712 in ethanol and DMF is approximately 20 mg/ml and approximately 10 mg/ml in DMSO.

Description

R-268712 is an inhibitor of activin receptor-like kinase (ALK5; IC₅₀ = 2.5 nM).¹ It is selective for ALK5 over p38 MAPK (IC₅₀ = 12 μM). R-268712 (1, 3, and 10 mg/kg) reduces renal fibrosis in a model of unilateral ureteral obstruction using transgenic Col1a1-Luc Tg rats, a reporter model for collagen I expression. It also reduces proteinuria and glomerulosclerosis and improves renal function in heminephrectomized rats in a model of glomerulonephritis using antibodies against Thy-1 membrane glycoprotein when administered at doses of 0.3 and 1 mg/kg.

Reference

1. Terashima, H., Kato, M., Ebisawa, M., *et al.* R-268712, an orally active transforming growth factor-β type I receptor inhibitor, prevents glomerular sclerosis in a Thy1 nephritis model. *Eur. J. Pharmacol.* **734**, 60-66 (2014).

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA
This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY
Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 07/19/2023

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM